Document detail
ID

oai:arXiv.org:2407.13849

Topic
Computer Science - Machine Learnin... Statistics - Machine Learning I.2.6
Author
Alabdallah, Abdallah Hamed, Omar Ohlsson, Mattias Rögnvaldsson, Thorsteinn Pashami, Sepideh
Category

Computer Science

Year

2024

listing date

7/24/2024

Keywords
proportional cox nam-based survival hazards senn networks neural model
Metrics

Abstract

The Cox Proportional Hazards (CPH) model has long been the preferred survival model for its explainability.

However, to increase its predictive power beyond its linear log-risk, it was extended to utilize deep neural networks sacrificing its explainability.

In this work, we explore the potential of self-explaining neural networks (SENN) for survival analysis.

we propose a new locally explainable Cox proportional hazards model, named CoxSE, by estimating a locally-linear log-hazard function using the SENN.

We also propose a modification to the Neural additive (NAM) models hybrid with SENN, named CoxSENAM, which enables the control of the stability and consistency of the generated explanations.

Several experiments using synthetic and real datasets have been performed comparing with a NAM-based model, DeepSurv model explained with SHAP, and a linear CPH model.

The results show that, unlike the NAM-based model, the SENN-based model can provide more stable and consistent explanations while maintaining the same expressiveness power of the black-box model.

The results also show that, due to their structural design, NAM-based models demonstrated better robustness to non-informative features.

Among these models, the hybrid model exhibited the best robustness.

Alabdallah, Abdallah,Hamed, Omar,Ohlsson, Mattias,Rögnvaldsson, Thorsteinn,Pashami, Sepideh, 2024, CoxSE: Exploring the Potential of Self-Explaining Neural Networks with Cox Proportional Hazards Model for Survival Analysis

Document

Open

Share

Source

Articles recommended by ES/IODE AI

Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial
gravis myasthenia study clinical phase baseline improvement mg-adl 340 week trial placebo period mg maintenance qw